PSMD3 and cancer: Altogether, these findings suggest that PSMD1 and PSMD3 mRNA expression could serve as novel prognostic biomarkers for cancers affecting multiple different tissue types, especially for patients with KICH who are progressing from stage 3 to stage 4 of the disease [31].